JPH0245639B2 - - Google Patents
Info
- Publication number
- JPH0245639B2 JPH0245639B2 JP56184198A JP18419881A JPH0245639B2 JP H0245639 B2 JPH0245639 B2 JP H0245639B2 JP 56184198 A JP56184198 A JP 56184198A JP 18419881 A JP18419881 A JP 18419881A JP H0245639 B2 JPH0245639 B2 JP H0245639B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- amino
- substance
- reference example
- diethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 32
- 239000000126 substance Substances 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- 230000000704 physical effect Effects 0.000 description 10
- -1 t-butoxycarbonyl group Chemical group 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 150000001793 charged compounds Chemical class 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 5
- 238000010531 catalytic reduction reaction Methods 0.000 description 5
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NNEHOKZDWLJKHP-LBPRGKRZSA-N (2s)-3-methyl-2-[methyl(phenylmethoxycarbonyl)amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)N(C)C(=O)OCC1=CC=CC=C1 NNEHOKZDWLJKHP-LBPRGKRZSA-N 0.000 description 2
- AATNZNJRDOVKDD-UHFFFAOYSA-N 1-[ethoxy(ethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CC)OCC AATNZNJRDOVKDD-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- JDTWZSUNGHMMJM-UHFFFAOYSA-N N-acetyl-DL-alloisoleucine Natural products CCC(C)C(C(O)=O)NC(C)=O JDTWZSUNGHMMJM-UHFFFAOYSA-N 0.000 description 2
- JDTWZSUNGHMMJM-FSPLSTOPSA-N N-acetyl-L-isoleucine Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(C)=O JDTWZSUNGHMMJM-FSPLSTOPSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RRONHWAVOYADJL-HNNXBMFYSA-N (2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-HNNXBMFYSA-N 0.000 description 1
- CGTRMQAGAQWBGX-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethylphosphonic acid Chemical compound OC1=CC=C(CCP(O)(O)=O)C=C1 CGTRMQAGAQWBGX-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
本発明は生理活性を有する含リンオリゴペプチ
ドおよびそれらの製造法に関する。
さらに詳しくは、本発明は
式(X)
〔式中、R2は水素、メチルまたはエチルを示
し、R4はメチルまたはアセチルを示し、R5は炭
素数1から4のアルキルを示し、R4は水素また
は水酸基を示す。但し、R2が水素、R4がアセチ
ル、R5がsec−ブチルのとき、R6は水酸基ではな
い。〕
で表わされる含リンオリゴペプチドに関する。上
記定義中、炭素数1から4のアルキルとしては、
メチル、エチル、イソプロピル、sec―ブチル、
イソブチルなどが例示される。
式()で表わされる化合物中下記式()で
表わされるN−(N−アセチル−L−イソロイシ
ル−L−チロシル)−(−)−1−アミノ−2−(4
−ヒドロキシフエニル)エチルホスホン酸ジエチ
ルエステルおよび式()で表わされるN(N−
メチル−L−バリル−L−フエニルアラニル)−
(−)−1−アミノ−2−(4−ヒドロキシフエニ
ル)エチルホスホン酸およびそのジエチルエステ
ルは本発明化合物の代表的例である。
〔式()で表わされる化合物は、式()に
おいてR2がエチル、R4がアセチル、R5が
The present invention relates to physiologically active phosphorus-containing oligopeptides and methods for producing them. More specifically, the present invention relates to formula (X) [In the formula, R 2 represents hydrogen, methyl or ethyl, R 4 represents methyl or acetyl, R 5 represents alkyl having 1 to 4 carbon atoms, and R 4 represents hydrogen or a hydroxyl group. However, when R 2 is hydrogen, R 4 is acetyl, and R 5 is sec-butyl, R 6 is not a hydroxyl group. ] The present invention relates to a phosphorus-containing oligopeptide represented by the following. In the above definition, alkyl having 1 to 4 carbon atoms is
Methyl, ethyl, isopropyl, sec-butyl,
Examples include isobutyl. Among the compounds represented by the formula (), N-(N-acetyl-L-isoleucyl-L-tyrosyl)-(-)-1-amino-2-(4
-Hydroxyphenyl)ethylphosphonic acid diethyl ester and N(N-
Methyl-L-valyl-L-phenylalanyl)-
(-)-1-Amino-2-(4-hydroxyphenyl)ethylphosphonic acid and its diethyl ester are representative examples of compounds of the present invention. [For the compound represented by formula (), R 2 is ethyl, R 4 is acetyl, and R 5 is
化合物−bはペプチド合成で通常用いられてい
るアミノ基の保護基を除去する方法で化合物−a
から得られる。
例えば、X1がベンジロキシカルボニル基の場
合には接触還元による方法で目的物を得ることが
できる。またt−ブトキシカルボニル基の場合に
は酸により容易に切断され目的物を得ることがで
きる。
本工程における化合物−aは新規化合物であ
り、本出願人が本出願と同時に出願する特願昭56
−184199号(特開昭58−85897号)に開示されて
いるが、具体的化合物ならびにその製造法につい
ては参考例に示す。
〔工程 2〕
化合物−cは化合物−bをアミノ基が保護され
たアミノ酸とペプチド結合させて得られる。アミ
ノ基が保護されたアミノ酸として、例えば、N−
アセチル−L−イソロイシンあるいはN−ベンジ
ロキシカルボニル−N−メチル−L−バリン等が
用いられ、一般にペプチド合成で用いられている
縮合剤の存在下に反応させ、通常に有機合成で用
いられている方法で分離、精製することにより得
られる。または上記のアミノ酸誘導体を一般にペ
プチド合成で用いられている活性エステル誘導体
に誘導した後に化合物−bを縮合させ、分離する
ことによつても化合物−cが得られる。
ここで用いられる縮合剤としては、例えば、
N,N′−ジシクロヘキシルカルボジイミド(以
下DCCと略す)またはDCCとN−ヒドロキシス
クシンイミドあるいはDCCと1−オキシベンゾ
トリアゾール等が用いうる。反応溶媒は、通常ペ
プチド合成に用いられる溶媒であり、例えばテト
ラヒドロフラン、エチレングリコール、ジメチル
エーテル等のエーテル類、N,N−ジメチルホル
ムアミド等のアミド類、塩化メチレン等のハロゲ
ン化炭化水素類等、またはこれらの混合物が用い
られる。活性エステルとして、上記アミノ酸誘導
体のP−ニトロフエニルエステル等の置換フエニ
ルエステル類、またはN−ヒドロキシスクシンイ
ミドエステル等のジカルボン酸イミドエステル類
あるいは上記アミノ酸の酸無水物等が用いられ
る。
〔工程 3〕
化合物−dはペプチド合成で通常用いられてい
るアミノ基あるいは水酸基の保護基を除去する方
法で化合物−cから得られる。例えばX2がベン
ジロキシカルボニル基の場合には接触還元による
方法で目的物を得ることができる。またt−ブト
キシカルボニル基の場合には酸により容易に切断
され目的物を得ることができる。さらに、Zがベ
ンジロキシカルボニル基、あるいはベンジル基等
の場合には、上記のX2と同様な方法により目的
物を得ることができる。
〔工程 4〕
化合物−eは化合物−dのリン酸エステルを加
水分解することにより得られる。例えば、化合物
−dを塩化水素あるいは臭化水素等を含む酢酸溶
液で反応させることにより、化合物−eが得られ
る。
以上の工程で得られる化合物−d、および化合
物−eは降圧作用を有している。
尚、化合物−eでR3がアセチル基、RがL−
イソロイシンのアルキル基部分、Yが水酸基で表
わされる化合物は同一出願人らにより、既に出願
されている生理活性物質K−26(特願昭56−
40651、特開昭57−156498)と同一の化合物であ
る。
なお、K−26の降圧作用を示す実験結果を次に
示す。
実験:観血的方法による降圧作用の測定
本実験は津田恭介ら編:薬効の評価(1)薬理試験
法(中)(医薬品開発基礎講座V)地文書館(昭
和46年10月10日発行)464〜468頁記載の方法に準
じて行つた。
実験動物としてSpontaneously Hypertensive
Rats(SHR)(雄性、体重300〜400g)1群3匹
を用いた。該ラツトにウレタン600mg/Kgおよび
α−クロラロース60mg/Kgを腹腔内投与して麻酔
した。気管カニユーレで気道を確保し、血圧を左
頚動脈に挿入したポリエチレンカニユーレから圧
トランスデユーサ(日本光電MP−0.5)を介して
インク−オシログラフイーに記録した。
薬物は、投与容量が0.1ml/100gとなるように
生理食塩水に溶解し、右股静脈に挿入したカニユ
ーレから静脈内投与し、麻酔下での血圧変化を測
定した。
平均血圧の変化を第1表に示す。尚投与直前の
4例の平均血圧は143.5±21.3mmHg(平均値±標準
誤差)を示す。
Compound-b was prepared by compound-a using a method that removes the protecting group of the amino group, which is commonly used in peptide synthesis.
obtained from. For example, when X 1 is a benzyloxycarbonyl group, the desired product can be obtained by catalytic reduction. Further, in the case of a t-butoxycarbonyl group, it can be easily cleaved with an acid to obtain the desired product. Compound-a in this step is a new compound, and the applicant filed a patent application in 1986 at the same time as this application.
-184199 (Japanese Unexamined Patent Publication No. 58-85897), specific compounds and methods for producing the same are shown in Reference Examples. [Step 2] Compound-c is obtained by peptide bonding compound-b with an amino acid whose amino group is protected. Examples of amino acids with protected amino groups include N-
Acetyl-L-isoleucine or N-benzyloxycarbonyl-N-methyl-L-valine is used, and is reacted in the presence of a condensing agent commonly used in peptide synthesis, which is commonly used in organic synthesis. It can be obtained by separating and purifying it by a method. Alternatively, Compound-c can also be obtained by deriving the above amino acid derivative into an active ester derivative generally used in peptide synthesis, condensing Compound-b, and separating the derivative. As the condensing agent used here, for example,
N,N'-dicyclohexylcarbodiimide (hereinafter abbreviated as DCC), DCC and N-hydroxysuccinimide, or DCC and 1-oxybenzotriazole can be used. The reaction solvent is a solvent normally used for peptide synthesis, such as ethers such as tetrahydrofuran, ethylene glycol, dimethyl ether, amides such as N,N-dimethylformamide, halogenated hydrocarbons such as methylene chloride, or the like. A mixture of is used. As the active ester, substituted phenyl esters such as P-nitrophenyl ester of the above amino acid derivatives, dicarboxylic acid imide esters such as N-hydroxysuccinimide ester, or acid anhydrides of the above amino acids are used. [Step 3] Compound-d is obtained from compound-c by a method that removes the protecting group for the amino group or hydroxyl group, which is commonly used in peptide synthesis. For example, when X 2 is a benzyloxycarbonyl group, the desired product can be obtained by catalytic reduction. Further, in the case of a t-butoxycarbonyl group, it can be easily cleaved with an acid to obtain the desired product. Furthermore, when Z is a benzyloxycarbonyl group or a benzyl group, the desired product can be obtained by the same method as for X 2 above. [Step 4] Compound-e is obtained by hydrolyzing the phosphoric acid ester of compound-d. For example, compound -e can be obtained by reacting compound -d with an acetic acid solution containing hydrogen chloride or hydrogen bromide. Compound-d and compound-e obtained in the above steps have a hypotensive effect. In compound-e, R 3 is an acetyl group and R is L-
A compound in which the alkyl group moiety of isoleucine, Y, is a hydroxyl group is a physiologically active substance K-26 (Japanese Patent Application No. 1983-1999), which has already been filed by the same applicant.
40651, JP-A-57-156498). The experimental results showing the hypotensive effect of K-26 are shown below. Experiment: Measurement of antihypertensive effect by invasive method This experiment was conducted by Kyosuke Tsuda et al.: Evaluation of drug efficacy (1) Pharmacological test methods (middle) (Basic drug development course V) National Archives (published October 10, 1972) ) The procedure was carried out according to the method described on pages 464-468. Spontaneously Hypertensive as a laboratory animal
Three Rats (SHR) (male, weight 300-400 g) were used in each group. The rats were anesthetized by intraperitoneally administering 600 mg/Kg of urethane and 60 mg/Kg of α-chloralose. The airway was secured with a tracheal cannula, and blood pressure was recorded on ink-oscillography via a pressure transducer (Nihon Kohden MP-0.5) from a polyethylene cannula inserted into the left carotid artery. The drug was dissolved in physiological saline in an administration volume of 0.1 ml/100 g, and administered intravenously through a cannula inserted into the right femoral vein, and changes in blood pressure under anesthesia were measured. Table 1 shows the changes in mean blood pressure. The average blood pressure of the four patients immediately before administration was 143.5±21.3 mmHg (mean value±standard error).
【表】
この結果K−26は降圧作用を有することがわか
る。
以下に本発明を実施例および参考例により詳し
く説明する。
実施例1〔工程 3〕
参考例5で得られた化合物15mgをメタノール2
mlに溶解し、10%・パラジウム−炭素10mgを加
え、室温下3.5時間接触還元を行なう。触媒を
別し、液を減圧留去後、クロロホルム:メタノ
ール=9:1の混合溶媒50mlに溶解し、短かめの
シリカゲルカラムクロマトグラフイーに通塔す
る。溶出液を減圧留去後、メタノールより再結晶
することにより、目的物である無色針状結晶10mg
(収率86%)を得る。
得られた化合物の物性が次に示される。
融点292〜294゜(dec.)
〔α〕22 D=−66.5゜(c0.10,MeOH)
IR(KBr):3240,1633,1544,1199,1049,
1020cm-1 1
H−NMR(CD3OD):主なピークはδ:0.71(d,
3H),0.82(t,3H),1.31(t,6H),1.94
(s,3H),4.1(m,4H),6.64(d,2H),
6.66(d,2H),7.00(d,2H),7.04(d,
2H)
本物質のマススペクトルは分子イオンピークを
m/z591に示す。
上記により本物質はN−(N−アセチル−L−
イソロイシル−L−チロシル)−(−)−1−アミ
ノ−2−(4−ヒドロキシフエニル)エチルホス
ホン酸ジエチルと特定される。
実施例2〔工程 3〕
参考例6で得られた化合物17mgをメタノール−
酢酸(9:1)1mlに溶解し、10%パラジウム−
炭素10mgを加え1日接触還元を行なう。触媒を
別後、液を減圧留去し、残査を分取用シリカゲ
ル薄層クロマトグラフイー(クロロホルム:メタ
ノール=9:1)にて分離して、目的化合物であ
る無色ガラス状物質6mg(収率41%)を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−40.9゜(c0.56,MeOH)
IR(CHCl3):3310,1673,1661,1509,1227,
1041,1020cm-1 1
H−NMR(CD3OD):主なピークはδ:0.70(d,
3H),0.76(d,3H),1.33(t,6H),1.93
(s,3H),2.62(d,1H),4.13(m,4H),
6.64(d,2H),7.04(d,2H),7.22(s,
5H)
本物質のマススペクトルは分子イオンピークを
m/z533に示す。
上記により本物質はN−(N−メチル−L−バ
リル−L−フエニルアラニル)−(−)−1−アミ
ノ−2−(4−ヒドロキシフエニル)エチルホス
ホン酸ジエチルと特定される。
実施例3〔工程 4〕
実施例2で得られた化合物1mgを20%・臭化水
素酸−酢酸溶液0.3mlに溶解し、室温下4時間放
置する。参考例7と同様な処理を行ない、粗生成
物0.5mgを得る。粗生成物を少量の0.04N−苛性ソ
ーダ水溶液に溶解し、高速液体クロマトグラフイ
ー(参考例7と同一の条件)にて保持時間1.8分
の部分を集める。濃縮後、凍結乾燥することによ
り、精製された目的化合物である白色固体を得
る。
得られた化合物の物性が次に示される。
融点:300℃以上1
H−NMR(D2O,pD11.9):主なピークはδ:
0.71(d,3H),0.79(d,3H),1.74(s,
3H),2.69(d,1H),4.08(bt,1H),6.53
(d,2H),7.01(d,2H),7.34(s,5H)
上記により本物質はN−(N−メチル−L−バ
リル−L−フエニルアラニル)−(−)−1−アミ
ノ−2−(4−ヒドロキシフエニル)エチルホス
ホン酸と特定される。
参考例 1
1−アミノ−2−(4−ベンジロキシフエニル)
エチルホスホン酸ジエチル138mgとN−t−ブト
キシカルボニル−0−ベンジル−L−チロシン
142mgおよびN−ヒドロキシスクシンイミド44mg
を無水エチレングリコールジメチルエーテル4ml
に溶解し、食塩・氷浴中で撹拌する。DCCを86
mg加え、冷却下2時間撹拌し、さらに室温下26時
間撹拌する。生成したN,N′−ジシクロヘキシ
ル尿素を別し、液に酢酸エチル100mlを加え、
水で洗浄後、無水硫酸ナトリウムで乾燥する。溶
媒を減圧留去後、残査を分取用シリカゲル薄層ク
ロマトグラフイーに付し、クロロホルム:アセト
ン=9:1の混合溶媒で展開すると、Rf=0.39と
Rf=0.27に分離される。Rf=0.39部分をかきと
り、同一の溶媒で溶出し、溶媒を減圧留去すると
目的化合物の無色ガラス状物質100mg(収率73%)
を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−40.2゜(c0.92,MeOH)
IR(CHCl3):1673,1504,1234,1042,1018cm-1 1
H−NMR(CDCl3):主なピークはδ:1.23(t,
3H),1.28(t,3H),1.38(s,9H),2.5〜
4.8(m,10H),4.99(s,2H),5.01(s,
2H),6.8〜7.1(m,8H),7.36(bs,10H)
本物質のマススペクトルは分子イオンピークを
m/z716に示す。
上記により本物質はN−(N−t−ブトキシカ
ルボニル−O−ベンジル−L−チロシル)−(−)
−1−アミノ−2−(4−ベンジロキシフエニル)
エチルホススン酸ジエチルと特定される。
参考例 2
1−アミノ−2−(4−ベンジロキシフエニル)
エチルホスホン酸ジエチル408mgとN−ベンジロ
キシカルボニル−L−フエニルアラニン336mgお
よびN−ヒドロキシスクシンイミド129mgを無水
エチレングリコールジメチルエーテル11mlに溶解
し、食塩・氷浴中で撹拌する。DCC225mgを加え
2.5時間撹拌する。その後、冷蔵庫(約5℃)中
に2.5日放置しておく。生成したN,N′−ジシク
ロヘキシル尿素を別し、液に酢酸エチル150
mlを加える。参考例5と同様な処理を行ない、残
査をシリカゲルカラムクロマトグラフイー(クロ
ロホルム:アセトン=9:1、同一の溶媒でのシ
リカゲル薄層クロマトグラフイーでRf=0.33、
Rf=0.25に分離される。)に付し、Rf=0.33の目
的化合物の無色ガラス状物質265mg(収率73%)
を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−48.5゜(c1.14,MeOH)
IR(CHCl3):1715,1677,1507,1231,1043,
1020cm-1 1
H−NMR(CDCl3):主なピークはδ:1.20(t,
3H),1.27(t,3H),2.6〜5.0(m,10H),
4.95(s,2H),5.01(s,2H),6.82(d,
2H),7.08(d,2H),7.1〜7.3(15H)
本物質のマススペクトルは分子イオンピークを
m/z644に示す。
上記により本物質はN−(N−ベンジロキシカ
ルボニル−L−フエニルアラニル)−(−)−1−
アミノ−2−(4−ベンジロキシフエニル)エチ
ルホスホン酸ジエチルと特定される。
参考例3〔工程 1〕
N−(N−t−ブトキシカルボニル−O−ベン
ジル−L−チロシル)−(−)−1−アミノ−2−
(4−ベンジロキシフエニル)エチルホスホン酸
ジエチル(参考例1参照)41mgを酢酸エチル4ml
に溶解後、10%−塩酸・メタノール溶液1mlを加
え、室温下1日撹拌する。酢酸エチル50mlを加
え、重曹水で洗浄後、水洗し、無水硫酸ナトリウ
ムで乾燥する。分取用シリカゲル薄層クロマトグ
ラフイー(クロロホルム:メタノール=95:5)
にて分離し、無色ガラス状物質26mg(収率73%)
を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−40.4゜(c0.92,MeOH)
IR(CHCl3):3340,1679,1505,1231,1044,
1019cm-1
本物質のマススペクトルは分子イオンピークを
m/z616に示す。
上記により、本物質はN−O−ベンジル−L−
チロシル)−(−)−1−アミノ−2−(4−ベンジ
ロキシフエニル)エチルホスホン酸ジエチルと特
定される。
参考例4〔工程 1〕
N−(N−ベンジロキシカルボニル−L−フエ
ニルアラニル−(−)−1−アミノ−2−(4−ベ
ンジロキシフエニル)エチルホスホン酸ジエチル
(参考例2参照)75mgをメタノール酢酸(4:1)
5mlに溶解し、10%・パラジウム−炭素40mgを加
え、8時間接触還元を行なう。触媒を別後、
液を減圧留去し、分取用シリカゲル薄層クロマト
グラフイー(クロロホルム:メタノール=9:
1)にて分離して、目的化合物である無色ガラス
状物質40mg(収率83%)を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−63.0゜(c1.36,MeOH)
IR(CHCl3):3320,1660,1508,1226,1041,
1020cm-1 1
H−NMR(CD3OD):主なピークはδ:1.29(m,
6H),2.5〜3.7(m,5H),4.1(m,4H),
4.56(m,1H),6.70(d,2H),7.05(d,
2H),7.2(5H)
本物質のマススペクトルは分子イオンピークを
m/z420に示す。
上記により本物質はN−(L−フエニルアラニ
ル)−(−)−1−アミノ−2−(4−ヒドロキシフ
エニル)エチルホスホン酸ジエチルと特定され
る。
参考例5〔工程 2〕
参考例3で得られた化合物26mg、N−アセチル
−L−イソロイシン7mgとN−ヒドロキシスクシ
ンイミド5mgを無水エチレングリコールジメチル
エーテル1mlに溶解し、食塩−氷浴中で撹拌す
る。DCC9mgを加え撹拌し、そのまま室温まで上
げ26時間反応させる。生成したN,N′−ジシク
ロヘキシル尿素を除去し、溶媒を減圧留去後、分
取用シリカゲル薄層クロマトグラフイー(クロロ
ホルム:メタノール=97:3)にて分離して、目
的化合物である白色固体15mg(収率46%)を得
る。得られた化合物の物性が次に示される。
融点:145〜147℃
〔α〕26 D=−46.4゜(c0.53,MeOH)
IR(CHCl3):3290,1650,1506,1230,1019cm-1 1
H−NMR(CD3OD)主なピークはδ:0.67(d,
3H),0.78(t,3H),1.30(t,6H),1.91
(s,3H),4.1(m,4H),5.00(s,4H),
6.84(d,2H),6.86(d,2H),7.09(d,
2H),7.13(d,2H),7.3(bs,10H)
本物質のマススペクトルは分子イオンピークを
m/z771に示す。
上記により、本物質はN−(N−アセチル−L
−イソロイシル−O−ベンジル−L−チロシル)
−(−)−1−アミノ−2−(4−ベンジロキシフ
エニル)エチルホスホン酸ジエチルと特定され
る。
参考例6〔工程 2〕
参考例4で得られた化合物40mg、N−ベンジロ
キシカルボニル−N−メチル−L−バリン26mg、
N−ヒドロキシスクシンイミド11mgを無水エチレ
ングリコールジメチルエーテル1mlに溶解し、食
塩・氷浴中で撹拌する。DCCをを22mg加え3時
間撹拌後、室温に上げ26時間撹拌する。生成した
N,N′−ジシクロヘキシル尿素を別し、液
に酢酸エチル50mlを加え、有機層を重曹水で洗浄
し、水洗後、無水硫酸ナトリウムで乾燥する。溶
媒を減圧留去後、残査を分取用シリカゲル薄層ク
ロマトグラフイー(クロロホルム:メタノール=
96:4)にて分離して、目的化合物である無色ガ
ラス状物質17mg(収率27%)を得る。
得られた化合物の物性が次に示される。
〔α〕26 D=−95.7゜(c0.68,MeOH)
IR(CHCl3):3410,1674,1509,1222,1040,
1020cm-1 1
H−NMR(CD3OD)主なピークはδ:0.76(d,
6H),1.33(t,6H),2.52(bs,3H),4.12
(m,4H),5.14(s,2H),6.66(d,2H),
7.05(d,2H),7.10(s,5H),7.37(s,
5H)
本物質のマススペクトルは分子イオンピークを
m/z667に示す。
上記により本物質はN−(N−ベンジロキシカ
ルボニル−N−メチル−L−バリル−L−フエニ
ルアラニル)−(−)−1−アミノ−2−(4−ヒド
ロキシフエニル)エチルホスホン酸ジエチルを特
定される。
参考例7〔工程 4〕
実施例1で得られた化合物2mgを20%臭化水素
酸−酢酸溶液0.3mlに溶解し、室温下4時間放置
する。反応液に水5mlを加え、2N−苛性ソーダ
水溶液でPH2に調整し、HP−20(三菱化成製、
非イオン性多孔性樹脂)に通塔し水で洗浄後、
0.1N−アンモニア性50%メタノール水溶液で溶
出し、溶媒を減圧乾固することにより粗生成物を
1mg得る。粗生成物を少量のメタノールに溶解
し、高速液体クロマトグラフイー〔μBondapack
C18〔ウオーターズ社製〕、0.01M−酢酸アンモニ
ウム(PH5.0):アセトニトリル=9:1、4ml/
min〕にて保持時間2.7分の部分を集める。濃縮
後、凍結乾燥することにより、精製された目的化
合物である白色固体を得る。
得られた化合物の物性が次に示される。
融点:300℃以上1
H−NMR(D2O,PD4.5):主なピークはδ:
0.65(d,3H),0.81(t,3H),2.00(s,
3H),3.99(d,1H),4.30(bt,1H),4.65
(dd,1H),6.83(d,4H),7.14(d,2H),
7.20(d,2H)
上記により本物質はN−(N−アセチル−L−
イソロイシル−L−チロシル)−(−)−1−アミ
ノ−2−(4−ヒドロキシフエニル)エチルホス
ホン酸と特定される。[Table] The results show that K-26 has a hypotensive effect. The present invention will be explained in detail below using Examples and Reference Examples. Example 1 [Step 3] 15 mg of the compound obtained in Reference Example 5 was mixed with methanol 2
ml, add 10 mg of 10% palladium on carbon, and perform catalytic reduction at room temperature for 3.5 hours. After separating the catalyst and distilling off the liquid under reduced pressure, it was dissolved in 50 ml of a mixed solvent of chloroform:methanol=9:1, and passed through a short silica gel column chromatography. After distilling off the eluate under reduced pressure, recrystallization from methanol yields 10 mg of the target product, colorless needle-like crystals.
(yield 86%). The physical properties of the obtained compound are shown below. Melting point 292-294° (dec.) [α] 22 D = -66.5° (c0.10, MeOH) IR (KBr): 3240, 1633, 1544, 1199, 1049,
1020cm -1 1 H-NMR (CD 3 OD): The main peak is δ: 0.71 (d,
3H), 0.82 (t, 3H), 1.31 (t, 6H), 1.94
(s, 3H), 4.1 (m, 4H), 6.64 (d, 2H),
6.66 (d, 2H), 7.00 (d, 2H), 7.04 (d,
2H) The mass spectrum of this substance shows a molecular ion peak at m/z591. According to the above, this substance is N-(N-acetyl-L-
It is identified as diethyl isoleucyl-L-tyrosyl)-(-)-1-amino-2-(4-hydroxyphenyl)ethylphosphonate. Example 2 [Step 3] 17 mg of the compound obtained in Reference Example 6 was dissolved in methanol.
10% palladium dissolved in 1 ml of acetic acid (9:1)
Add 10 mg of carbon and perform catalytic reduction for one day. After separating the catalyst, the liquid was distilled off under reduced pressure, and the residue was separated by preparative silica gel thin layer chromatography (chloroform:methanol = 9:1) to obtain 6 mg of a colorless glassy substance (yield), which is the target compound. rate of 41%). The physical properties of the obtained compound are shown below. [α] 26 D = −40.9° (c0.56, MeOH) IR (CHCl 3 ): 3310, 1673, 1661, 1509, 1227,
1041, 1020cm -1 1 H-NMR (CD 3 OD): The main peak is δ: 0.70 (d,
3H), 0.76 (d, 3H), 1.33 (t, 6H), 1.93
(s, 3H), 2.62 (d, 1H), 4.13 (m, 4H),
6.64 (d, 2H), 7.04 (d, 2H), 7.22 (s,
5H) The mass spectrum of this substance shows a molecular ion peak at m/z533. Based on the above, this substance is identified as diethyl N-(N-methyl-L-valyl-L-phenylalanyl)-(-)-1-amino-2-(4-hydroxyphenyl)ethylphosphonate. Example 3 [Step 4] 1 mg of the compound obtained in Example 2 was dissolved in 0.3 ml of 20% hydrobromic acid-acetic acid solution and left at room temperature for 4 hours. The same treatment as in Reference Example 7 was carried out to obtain 0.5 mg of a crude product. The crude product was dissolved in a small amount of 0.04N aqueous sodium hydroxide solution, and a portion with a retention time of 1.8 minutes was collected using high performance liquid chromatography (same conditions as Reference Example 7). After concentration, a white solid, which is the purified target compound, is obtained by freeze-drying. The physical properties of the obtained compound are shown below. Melting point: 300℃ or higher 1 H-NMR (D 2 O, pD11.9): Main peak is δ:
0.71 (d, 3H), 0.79 (d, 3H), 1.74 (s,
3H), 2.69 (d, 1H), 4.08 (bt, 1H), 6.53
(d, 2H), 7.01 (d, 2H), 7.34 (s, 5H) According to the above, this substance is N-(N-methyl-L-valyl-L-phenylalanyl)-(-)-1-amino-2- It is identified as (4-hydroxyphenyl)ethylphosphonic acid. Reference example 1 1-amino-2-(4-benzyloxyphenyl)
138 mg of diethyl ethylphosphonate and N-t-butoxycarbonyl-0-benzyl-L-tyrosine
142mg and N-hydroxysuccinimide 44mg
4 ml of anhydrous ethylene glycol dimethyl ether
and stir in a salt/ice bath. DCC86
mg was added, stirred for 2 hours under cooling, and further stirred at room temperature for 26 hours. Separate the generated N,N'-dicyclohexylurea, add 100 ml of ethyl acetate to the liquid,
After washing with water, dry with anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was subjected to preparative silica gel thin layer chromatography and developed with a mixed solvent of chloroform:acetone = 9:1, giving Rf = 0.39.
Separated by Rf=0.27. The Rf = 0.39 portion was scraped off, eluted with the same solvent, and the solvent was distilled off under reduced pressure to yield 100 mg of a colorless glassy substance containing the target compound (yield 73%).
get. The physical properties of the obtained compound are shown below. [α] 26 D = −40.2° (c0.92, MeOH) IR (CHCl 3 ): 1673, 1504, 1234, 1042, 1018 cm -1 1 H-NMR (CDCl 3 ): The main peak is δ: 1.23 ( t,
3H), 1.28 (t, 3H), 1.38 (s, 9H), 2.5~
4.8 (m, 10H), 4.99 (s, 2H), 5.01 (s,
2H), 6.8-7.1 (m, 8H), 7.36 (bs, 10H) The mass spectrum of this substance shows a molecular ion peak at m/z716. According to the above, this substance is N-(N-t-butoxycarbonyl-O-benzyl-L-tyrosyl)-(-)
-1-amino-2-(4-benzyloxyphenyl)
Identified as diethyl ethylphosunate. Reference example 2 1-amino-2-(4-benzyloxyphenyl)
408 mg of diethyl ethylphosphonate, 336 mg of N-benzyloxycarbonyl-L-phenylalanine and 129 mg of N-hydroxysuccinimide are dissolved in 11 ml of anhydrous ethylene glycol dimethyl ether and stirred in a salt/ice bath. Add 225mg of DCC
Stir for 2.5 hours. After that, leave it in the refrigerator (approximately 5℃) for 2.5 days. Separate the generated N,N'-dicyclohexyl urea and add 150 ml of ethyl acetate to the liquid.
Add ml. The same treatment as in Reference Example 5 was carried out, and the residue was subjected to silica gel column chromatography (chloroform:acetone = 9:1, silica gel thin layer chromatography using the same solvent, Rf = 0.33,
Separated to Rf=0.25. ), 265 mg of colorless glassy substance of the target compound with Rf = 0.33 (yield 73%)
get. The physical properties of the obtained compound are shown below. [α] 26 D = −48.5° (c1.14, MeOH) IR (CHCl 3 ): 1715, 1677, 1507, 1231, 1043,
1020cm -1 1 H-NMR (CDCl 3 ): The main peak is δ: 1.20 (t,
3H), 1.27 (t, 3H), 2.6-5.0 (m, 10H),
4.95 (s, 2H), 5.01 (s, 2H), 6.82 (d,
2H), 7.08 (d, 2H), 7.1-7.3 (15H) The mass spectrum of this substance shows a molecular ion peak at m/z644. According to the above, this substance is N-(N-benzyloxycarbonyl-L-phenylalanyl)-(-)-1-
It is identified as diethyl amino-2-(4-benzyloxyphenyl)ethylphosphonate. Reference Example 3 [Step 1] N-(N-t-butoxycarbonyl-O-benzyl-L-tyrosyl)-(-)-1-amino-2-
41 mg of diethyl (4-benzyloxyphenyl)ethylphosphonate (see Reference Example 1) was added to 4 ml of ethyl acetate.
After dissolving in , add 1 ml of 10% hydrochloric acid/methanol solution and stir at room temperature for 1 day. Add 50 ml of ethyl acetate, wash with aqueous sodium bicarbonate, then water, and dry over anhydrous sodium sulfate. Preparative silica gel thin layer chromatography (chloroform:methanol = 95:5)
26 mg of colorless glassy substance (yield 73%)
get. The physical properties of the obtained compound are shown below. [α] 26 D = −40.4° (c0.92, MeOH) IR (CHCl 3 ): 3340, 1679, 1505, 1231, 1044,
1019cm -1 The mass spectrum of this substance shows a molecular ion peak at m/z616. According to the above, this substance is N-O-benzyl-L-
It is identified as diethyl tyrosyl)-(-)-1-amino-2-(4-benzyloxyphenyl)ethylphosphonate. Reference Example 4 [Step 1] 75 mg of diethyl N-(N-benzyloxycarbonyl-L-phenylalanyl-(-)-1-amino-2-(4-benzyloxyphenyl)ethylphosphonate) (see Reference Example 2) Methanol acetic acid (4:1)
Dissolve in 5 ml, add 40 mg of 10% palladium-carbon, and perform catalytic reduction for 8 hours. After separating the catalyst,
The liquid was distilled off under reduced pressure and subjected to preparative silica gel thin layer chromatography (chloroform: methanol = 9:
Separation is performed in step 1) to obtain 40 mg (yield: 83%) of a colorless glassy substance, which is the target compound. The physical properties of the obtained compound are shown below. [α] 26 D = −63.0° (c1.36, MeOH) IR (CHCl 3 ): 3320, 1660, 1508, 1226, 1041,
1020cm -1 1 H-NMR (CD 3 OD): The main peak is δ: 1.29 (m,
6H), 2.5-3.7 (m, 5H), 4.1 (m, 4H),
4.56 (m, 1H), 6.70 (d, 2H), 7.05 (d,
2H), 7.2 (5H) The mass spectrum of this substance shows a molecular ion peak at m/z420. Based on the above, this substance is identified as diethyl N-(L-phenylalanyl)-(-)-1-amino-2-(4-hydroxyphenyl)ethylphosphonate. Reference Example 5 [Step 2] 26 mg of the compound obtained in Reference Example 3, 7 mg of N-acetyl-L-isoleucine, and 5 mg of N-hydroxysuccinimide are dissolved in 1 ml of anhydrous ethylene glycol dimethyl ether and stirred in a salt-ice bath. Add 9 mg of DCC, stir, and then raise to room temperature and allow to react for 26 hours. The generated N,N'-dicyclohexylurea was removed, the solvent was distilled off under reduced pressure, and the target compound, a white solid, was separated using preparative silica gel thin layer chromatography (chloroform:methanol = 97:3). Obtain 15 mg (46% yield). The physical properties of the obtained compound are shown below. Melting point: 145-147℃ [α] 26 D = -46.4゜ (c0.53, MeOH) IR (CHCl 3 ): 3290, 1650, 1506, 1230, 1019 cm -1 1 H-NMR (CD 3 OD) Main The peak is δ: 0.67 (d,
3H), 0.78 (t, 3H), 1.30 (t, 6H), 1.91
(s, 3H), 4.1 (m, 4H), 5.00 (s, 4H),
6.84 (d, 2H), 6.86 (d, 2H), 7.09 (d,
2H), 7.13 (d, 2H), 7.3 (bs, 10H) The mass spectrum of this substance shows a molecular ion peak at m/z771. According to the above, this substance is N-(N-acetyl-L
-isoleucyl-O-benzyl-L-tyrosyl)
It is identified as diethyl -(-)-1-amino-2-(4-benzyloxyphenyl)ethylphosphonate. Reference Example 6 [Step 2] 40 mg of the compound obtained in Reference Example 4, 26 mg of N-benzyloxycarbonyl-N-methyl-L-valine,
11 mg of N-hydroxysuccinimide is dissolved in 1 ml of anhydrous ethylene glycol dimethyl ether and stirred in a salt/ice bath. Add 22 mg of DCC and stir for 3 hours, then raise to room temperature and stir for 26 hours. The generated N,N'-dicyclohexylurea is separated, 50 ml of ethyl acetate is added to the liquid, and the organic layer is washed with aqueous sodium bicarbonate, water, and dried over anhydrous sodium sulfate. After distilling off the solvent under reduced pressure, the residue was subjected to preparative silica gel thin layer chromatography (chloroform: methanol =
96:4) to obtain 17 mg (yield 27%) of a colorless glassy substance, which is the target compound. The physical properties of the obtained compound are shown below. [α] 26 D = −95.7° (c0.68, MeOH) IR (CHCl 3 ): 3410, 1674, 1509, 1222, 1040,
1020cm -1 1 H-NMR (CD 3 OD) main peak is δ: 0.76 (d,
6H), 1.33 (t, 6H), 2.52 (bs, 3H), 4.12
(m, 4H), 5.14 (s, 2H), 6.66 (d, 2H),
7.05 (d, 2H), 7.10 (s, 5H), 7.37 (s,
5H) The mass spectrum of this substance shows a molecular ion peak at m/z667. Based on the above, this substance is identified as diethyl N-(N-benzyloxycarbonyl-N-methyl-L-valyl-L-phenylalanyl)-(-)-1-amino-2-(4-hydroxyphenyl)ethylphosphonate. be done. Reference Example 7 [Step 4] 2 mg of the compound obtained in Example 1 was dissolved in 0.3 ml of 20% hydrobromic acid-acetic acid solution and left at room temperature for 4 hours. Add 5 ml of water to the reaction solution, adjust the pH to 2 with a 2N aqueous solution of caustic soda, and add HP-20 (manufactured by Mitsubishi Kasei,
After passing through the column (non-ionic porous resin) and washing with water,
Elution was performed with a 0.1N ammoniacal 50% aqueous methanol solution, and the solvent was dried under reduced pressure to obtain 1 mg of a crude product. The crude product was dissolved in a small amount of methanol and subjected to high performance liquid chromatography [μBondapack
C 18 [manufactured by Waters], 0.01M ammonium acetate (PH5.0):acetonitrile = 9:1, 4ml/
min] with a retention time of 2.7 minutes. After concentration, a white solid, which is the purified target compound, is obtained by freeze-drying. The physical properties of the obtained compound are shown below. Melting point: 300℃ or higher 1 H-NMR (D 2 O, PD4.5): Main peak is δ:
0.65 (d, 3H), 0.81 (t, 3H), 2.00 (s,
3H), 3.99 (d, 1H), 4.30 (bt, 1H), 4.65
(dd, 1H), 6.83 (d, 4H), 7.14 (d, 2H),
7.20(d,2H) According to the above, this substance is N-(N-acetyl-L-
It is identified as isoleucyl-L-tyrosyl)-(-)-1-amino-2-(4-hydroxyphenyl)ethylphosphonic acid.
Claims (1)
し、R4はメチルまたはアセチルを示し、R5は炭
素数1から4のアルキルを示し、R6は水素また
は水酸基を示す。但し、R2が水素、R4がアセチ
ル、R5がsec−ブチルのとき、R6は水酸基ではな
い。〕 で表わされる含リンオリゴペプチド。[Claims] 1 Formula () [In the formula, R 2 represents hydrogen, methyl or ethyl, R 4 represents methyl or acetyl, R 5 represents alkyl having 1 to 4 carbon atoms, and R 6 represents hydrogen or a hydroxyl group. However, when R 2 is hydrogen, R 4 is acetyl, and R 5 is sec-butyl, R 6 is not a hydroxyl group. ] A phosphorus-containing oligopeptide represented by
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56184198A JPS5885896A (en) | 1981-11-17 | 1981-11-17 | Phosphorus-containing oligopeptide and its preparation |
EP19820102277 EP0061172B1 (en) | 1981-03-20 | 1982-03-19 | Phosphorus-containing oligopeptides, processes for preparation thereof and a pharmaceutical composition containing the same |
DE8282102277T DE3264212D1 (en) | 1981-03-20 | 1982-03-19 | Phosphorus-containing oligopeptides, processes for preparation thereof and a pharmaceutical composition containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56184198A JPS5885896A (en) | 1981-11-17 | 1981-11-17 | Phosphorus-containing oligopeptide and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5885896A JPS5885896A (en) | 1983-05-23 |
JPH0245639B2 true JPH0245639B2 (en) | 1990-10-11 |
Family
ID=16149065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56184198A Granted JPS5885896A (en) | 1981-03-20 | 1981-11-17 | Phosphorus-containing oligopeptide and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5885896A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5951294A (en) * | 1982-09-17 | 1984-03-24 | Kyowa Hakko Kogyo Co Ltd | Phosphorus-containing peptide derivative |
JPS5951295A (en) * | 1982-09-17 | 1984-03-24 | Kyowa Hakko Kogyo Co Ltd | Phosphorus-containing peptide |
-
1981
- 1981-11-17 JP JP56184198A patent/JPS5885896A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5885896A (en) | 1983-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4294832A (en) | Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof | |
JPH05155898A (en) | Amidinophenylalanine derivative and preparation thereof | |
JPS63258449A (en) | Novel compound having collagenase inhibiting activity, its production and pharmacological composition containing said compound | |
EP0611375A1 (en) | Peptides inhibiting il-1 beta release | |
HU190486B (en) | Process for producing spiro /4./3+n// -2-azaalkane-3-carboxylic acid-derivatives and pharmaceutical compositions containing the same | |
JPS6259296A (en) | Peptide derivative | |
CZ246697A3 (en) | Proline derivatives, process of their preparation and pharmaceutical composition containing thereof | |
US4593018A (en) | Oligopeptide aldehydes useful as specific inhibitors of enterokinase | |
JPS6055506B2 (en) | Novel ω-aminocarboxylic acid amide and its production method | |
JP2653976B2 (en) | Novel phosphonic acids, methods for their preparation and pharmaceutical compositions containing them | |
JPH0662601B2 (en) | Cromoglycic acid derivative and anti-allergic agent | |
US4087520A (en) | Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides | |
JPH0570635B2 (en) | ||
JPH0245639B2 (en) | ||
US4496584A (en) | Amidine derivatives with anti-complement activity | |
EP0712838A1 (en) | Acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient | |
JPH0148915B2 (en) | ||
US5220002A (en) | Deacetylcolchicine derivatives | |
KR101247137B1 (en) | Process for the preparation of N-[O-(P-Pivaloyloxybenzenesulfonylamino)-benzoyl]glycin and for the formulation of the lyophilization containing its mononatrium saltㆍ4 hydrate | |
JPH0414120B2 (en) | ||
JP2578044B2 (en) | Phenylalanine-glycine derivative, method for producing the same, and antitumor agent containing the derivative | |
JPS62132846A (en) | 4-aminobutanoic acid derivative and manufacture | |
JPS5825661B2 (en) | N-acyl-1-acyl-4-guanidinobutylamine and its acid addition salt | |
JPH083172A (en) | Phenylboronic acid derivative and its production | |
JPH0339077B2 (en) |